Winners of the 2021 Call for Basic Research have been selected from all over Italy to study the still obscure portions of our genetic heritage.
Thanks to the alliance between Fondazione Cariplo and Fondazione Telethon, 24 basic research projects have been funded for a total of 5.7 million euros. The goal of the joint initiative is to understand genetic aspects and molecular mechanisms that are still largely unknown or poorly understood today, but potentially useful in aiding the development of new therapies for rare diseases.
Although the human genome has been completely sequenced, about one-third of human proteins have not yet been described. This unexplored portion of the genome could help elucidate new physiological and pathological mechanisms and could represent a wealth of information for discovering new therapeutic pathways. The call for proposals by Fondazione Cariplo and Fondazione Telethon therefore aimed to support basic research in this area, drawing inspiration from a National Institutes of Health (NIH) initiative focused on the study of those parts of our genetic heritage that, to date, remain obscure but should be "illuminated". Specifically, the projects have to be focused on the study of T-dark targets, defined according to criteria established by the Illuminating the Druggable Genome Knowledge Management Center (IDG-KMC), for which information on structure, function and interaction with molecules and drugs is unknown.
The 24 selected projects feature 35 research groups spread across the country: Campania, Lazio, Liguria, Lombardy, Tuscany, Molise, Trentino-Alto Adige and Veneto. More than 15 areas and diseases are going to be studied, including neurodevelopmental and growth disorders, rheumatological diseases, kidney diseases, neurological diseases, muscular dystrophy, Rett syndrome, Huntington's disease, a rare and genetic form of Alzheimer's disease, blood diseases, and mitochondrial diseases.
A total of more than 200 project proposals were received, and submitted by Italian nonprofit, public, or private research organizations. Of these, 132 were deemed eligible and proceeded to the evaluation process, which was performed by a scientific committee of 15 internationally renowned scientists from around the world and chaired by Dr. Massimo Pandolfo from McGill University in Montreal, Canada. To ensure the transparency and fairness of the evaluation, the method of peer-review was used, which indicates the critical evaluation that a paper or publication receives from specialists with similar expertise to that of the applicants.
«Basic research, particularly with regard to rare diseases, is still today an orphan area of investment, and this limits the number of studies launched, particularly in completely unexplored areas – says Francesca Pasinelli, General Director of Fondazione Telethon. – Actually, basic research represents a forerunner for innovation in general, developing key knowledge that is also potentially useful for applied research in the field of more frequent pathologies. In light of these considerations, Fondazione Telethon and Fondazione Cariplo decided to create this alliance with the common goal of fostering the growth of scientific research through projects whose results can over time address the unmet needs of patients and their families, in areas with few or no therapeutic options. We are therefore very happy with this partnership, which will continue in the coming years, and we hope that other Foundations will also follow Cariplo's example by pooling resources and expertise to support research on rare diseases».
«The last two years have clearly shown us the innovative and generative capacity of basic research, capable of creating that common ground from which discoveries arise over time that radically change people's lives. Fondazione Cariplo has always supported research and continues to do so today alongside the Fondazione Telethon, which shares with us the urgency of trying to give answers to those people who find themselves in particularly difficult conditions – concludes Giovanni Fosti, President of Fondazione Cariplo. – Facing the current challenges and complexity, networking and the sharing of knowledge are increasingly necessary».
List of funded projects
Campania
- Immacolata Andolfo - Università di Napoli Federico II (coordinator): “Exploring mTOR pathway in PIEZO1 activating signaling”
Lazio
- Matthieu Boulard - European Molecular Biology Laboratory (EMBL), Monterotondo (Roma): “Systematic discovery of previously unknown genes involved in Beckwith–Wiedemann and Silver–Russell syndromes”
- Salvatore Fusco - Università Cattolica del Sacro Cuore, Roma: “Role of ZDHHC proteins in Early-onset familial autosomal dominant Alzheimer disease”
Liguria
- Maria Carla Bosco - Istituto Giannina Gaslini, Genova: “MIR22HG in the pathogenic mechanisms of Oligoarticular Juvenile Idiopathic Arthritis: effects of its targeting”
Lombardy
- Isabella Barbiero - Università dell'Insubria, Varese: “Functional characterization of the InSyn1-CDKL5 interaction for dystrophin/dystroglycan complex dependent inhibitory synapse formation”
- Vania Broccoli - CNR, Istituto di Neuroscienze, Milano (coordinator): “Dissecting the pathomolecular mechanisms of Prr12 gene inactivation leading to neurodevelopmental and eye abnormalities”
- Francesca Ficara - CNR, Istituto di Ricerca Genetica e Biomedica, Milano: “Exploring the Role of Mediator Complex Subunit 12-like (MED12L) in rare myeloid neoplasms”
- Nicoletta Landsberger - Università di Milano (coordinator), Davide Pozzi - Humanitas University, Milano: “The interplay between HPCAL4 and MeCP2: identification and characterization of a novel putative target for Rett syndrome therapy”
- Chiara Lanzuolo - Fondazione Istituto Nazionale di Genetica Molecolare (INGM), Milano (coordinator), Francesco Ferrari - CNR, Istituto di Genetica Molecolare, Milano (partner): “Dissecting MLIP role in the molecular cascade triggered by lamina dysfunction in Emery Dreifuss Muscular Dystrophy”
- Francesca Lavatelli – Università di Pavia (coordinator), Pierluigi Mauri - CNR, Istituto di Tecnologie Biomediche, Milano (partner): “AL amyloidosis: gene restriction reveals the hidden molecular basis of amyloid transformation of immunoglobulin light chains”
- Marianna Leonzino - CNR, Istituto di Neuroscienze, Milano: “Defining VPS13D’s function(s) to reveal the pathogenetic mechanism causing VPS13D-linked movement disorders”
- Enrico Milan - Università Vita Salute San Raffaele, Milano: “Characterizing the molecular functions of TENT5/FAM46 proteins”
- Silvia Kristen Nicolis - Università di Milano Bicocca: “A CRISPR-Cas9-based high-throughput screen in human brain organoids of T-dark putative downstream effectors of SOX2 in neurodevelopmental disease”
- Maria Passafaro – CNR, Istituto di Neuroscienze, Milano: “Assessing the consequences of AMPARs defective transport in an AP4 deficiency mouse model”
- Luca Rampoldi - Università Vita Salute San Raffaele, Milano (coordinator): “Role of quality control in the early secretory compartment in Autosomal Dominant Tubulointerstitial Kidney Disease”
- Andrea Saponaro – Università di Milano (coordinator), Ivan Torrente – Università di Milano (partner): “At the origin of congenital muscular dystrophy: shedding light on the Tdark proteins DPM2 and DPM3”
- Alessandro Sessa - Università Vita Salute San Raffaele, Milano: “Exploring the epigenetic rewiring associated to RLF mutations as a driver of intellectual disability”
- Laura Silvestri - Università Vita Salute San Raffaele, Milano (partner): “Exploring mTOR pathway in PIEZO1 activating signaling”
- Enza Maria Valente – Università di Pavia: “Functional characterization of FSD1L: a novel "master regulator" of neurodevelopment?”
Molise
- Vittorio Maglione - Fondazione Neuromed, Pozzilli (IS, partner): “Discovery of novel genes involved in Huntington's Disease pathogenesis”
Tuscany
- Massimiliano Andreazzoli - Università di Pisa (partner): “Dissecting the pathomolecular mechanisms of Prr12 gene inactivation leading to neurodevelopmental and eye abnormalities”
- Simone Ciofi Baffoni - Università di Firenze (partner): “Mitochondrial myopathy associated to FDX2 mutations: a crossroad of FeS protein biogenesis and Coenzyme Q biosynthesis”
- Filippo Maria Santorelli - Fondazione Stella Maris – IRCCS, Calambrone (PI, coordinator): “Delving into the mechanisms underlying HPDL-related disorders with a multi-model approach”
Trentino-Alto Adige
- Luca Fava - Università di Trento: “Centriolar distal appendage: one nanoscopic structure, many diseases”
Veneto
- Paola Costantini - Università di Padova (coordinator): “Mitochondrial myopathy associated to FDX2 mutations: a crossroad of FeS protein biogenesis and Coenzyme Q biosynthesis”
- Diego De Stefani - Università di Padova (coordinator), Diana Pendin - CNR, Istituto di Neuroscienze, Padova (partner): “Deorphanizing and functionalizing the mitochondrial protein TMEM65”
- Erika Fernandez-Vizarra - Istituto Veneto di Medicina Molecolare (VIMM), Padova: “Pathological molecular mechanisms underlying APOPT1 loss of function”
- Graziano Martello – Università di Padova (coordinator): “Discovery of novel genes involved in Huntington's Disease pathogenesis”
- Leonardo Salviati - Istituto di Ricerca Pediatrica Città della Speranza (IRP), Padova (partner): “Delving into the mechanisms underlying HPDL-related disorders with a multi-model approach”
- Andrea Vettori - Università di Verona (partner): “Role of quality control in the early secretory compartment in Autosomal Dominant Tubulointerstitial Kidney Disease”